Literature DB >> 25539826

Ofatumumab: a novel treatment for severe systemic lupus erythematosus.

C Clare Thornton1, Nicola Ambrose1, Yiannis Ioannou2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25539826     DOI: 10.1093/rheumatology/keu475

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  7 in total

1.  Ofatumumab treatment in lupus nephritis patients.

Authors:  Malena Loberg Haarhaus; Elisabet Svenungsson; Iva Gunnarsson
Journal:  Clin Kidney J       Date:  2016-06-05

2.  Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.

Authors:  Md Yuzaiful Md Yusof; Daniel Shaw; Yasser M El-Sherbiny; Emma Dunn; Andy C Rawstron; Paul Emery; Edward M Vital
Journal:  Ann Rheum Dis       Date:  2017-07-06       Impact factor: 19.103

3.  Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review.

Authors:  Dominik Samotij; Adam Reich
Journal:  Biomed Res Int       Date:  2019-07-18       Impact factor: 3.411

Review 4.  Emerging B-Cell Therapies in Systemic Lupus Erythematosus.

Authors:  Ayse Bag-Ozbek; Joyce S Hui-Yuen
Journal:  Ther Clin Risk Manag       Date:  2021-01-14       Impact factor: 2.423

5.  Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series.

Authors:  Stephen P McAdoo; Rachna Bedi; Ruth Tarzi; Megan Griffith; Charles D Pusey; Thomas D Cairns
Journal:  Rheumatology (Oxford)       Date:  2016-04-19       Impact factor: 7.580

6.  Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ.

Authors:  Linda Lei; Sabina Muhammad; Muthana Al-Obaidi; Neil Sebire; Iek Leng Cheng; Despina Eleftheriou; Paul Brogan
Journal:  Pediatr Rheumatol Online J       Date:  2018-09-26       Impact factor: 3.054

7.  Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab.

Authors:  Sabih Ul Hassan; Md Yuzaiful Md Yusof; Paul Emery; Shouvik Dass; Edward M Vital
Journal:  Front Med (Lausanne)       Date:  2020-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.